Ministry of Health



These follow-up guidelines have been developed and discussed over 3 successive meetings of the NZ Gynecological Cancer group (NZGCG) during 2014 and 2015. In the absence of good evidence in this area, a consensus has been reached, taking into account opinions and practices around NZ and involving Medical and Nursing in the NZGCG .Endometrial CancerMajority of recurrence in first 2-3y ~80% by 3yMajority will have symptomsEarly stage – 2-15% recurAdvanced stage – up to 50% recur~50% of recurrence is local only Many local recurrences are curableNo evidence for routine smears or imagingIf subtotal hysterectomy done – needs cervical smears as per screening programme/risk of recurrenceSee 2 weeks post op for diagnosisAll patients discussed at MDMPelvic exam at each appointmentAlternate follow up Surgeon and Radiation Oncologist as appropriateEndometrial CancerLow Risk - Stage IA G1, 23 mth6mth1y18m2y5yGynaecological Surgeon X XCollect 5yr data outcomesSpecialist Nurse* XSPExit SPGP X XConsider virtual clinic for well motivated/very rural patientsDischarge at 2 years if no symptoms/ongoing concerns*3mth and 2y nurse led survivorship clinic is recommendedIntermediate Risk – Stages IA G3, IB Grades 1, 2 6weeks6mth1y1.5y2y2.5y3y5yRad Onc/SurgeonPost treatmentXXXXXXCollect clinical outcome dataCNSSurvivorshipPlan (SP)ExitSPIf no radiotherapy then follow up by surgeon at 6 monthly intervalsDischarge at 3 years if no symptoms/ongoing concernsHigh Risk - Stages IB G3, II, III, Serous, Clear cell, Carcinosarcoma6wk3mth6mth9mth1y1.5y2y2.5y3y5yRad Onc/SurgeonXXXXXXXXXData outcome collectionCNSSPExitSPIf no radiotherapy, surgical follow up onlyIf chemotherapy given, consider Medical Oncology follow up annuallyDischarge at 3years if no ongoing symptoms/concernsConsider earlier discharge if not fit/no salvage options availableCervical Cancer>75% of recurrences occur in first 2-3yLocal recurrences may be salvagedMajority will have symptomsNeed annual data collectionStage IA1 SCC Rx Surgery only 6 mth1y2yGynaecologistX smearGPX smear and HPVX smear and HPVTAH and cone biopsy treated the sameOnce 2 consecutive negative HPV tests, return to routine screeningStage IB1, IA2 & all IA adenocarcinoma - Surgical management3mth6m9m12m18m24m3 y5 yGynaecologist*(Radiation oncologist))XXXXXXOnly if RTData outcome collectionCNSX*SPX 9-18 monthfollowupXSPDischarge to GP at 2 yearsAnnual smears ongoing by GP if no radiation Rx (at least 10y)If radiotherapy given, alternate with Radiation Oncologist as appropriate. Continue to 3 years if had radiotherapy (for toxicity) then discharge to GP* Survivorship PlanPrimary Radiotherapy +/- chemo6w3 mth6912182y2.5y3y5yRad Onc/ GynaecologistXXXXXXXXXData outcome collectionCNSXSPX12-18mfollowupXSPDischarge at 3 years if no symptoms /ongoing concernsNo routine smearsFollow up: NotesClinical Nurse Specialist (CNS) – Nurse-led clinics for survivorship plan (SP) soon after all treatment completed and again at dischargeEducation for patients (oral and written) regarding symptoms of recurrence, lifestyle changes (especially weight control and stop smoking), support services, managing toxicityAnnual follow up data collectionPatient initiated follow up (PIFU) Make space in clinics for patients with symptoms to be seen quicklyThese recommendations are a guide only for the well patient – physician preferences may differ.Any symptoms/patient concerns require more intensive follow upReferencesDue to lack of evidence in the literature, these guidelines are based on the below:SGO recommendations - Salani et al AJOG 2011;204(6):466-78 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download